Key Drivers
- Strong liquidity
- Robust free cash
- Moderate returns
AIAI Summary
Merit is no longer a pure growth compounder but a cash-rich medtech with event-driven upside contingent on flawless commercialization and tariff/regulatory stability—investors should focus on sustained FCF conversion, evidence of tariff cost pass‑throughs, and early sales traction for new stents as the triggers that validate the current premium. If those fail to materialize (or if China/OEM weakness and regulatory costs persist), be prepared for meaningful multiple compression and downside; a pragmatic entry requires reclaiming the 21‑day MA on volume or clear margin resilience.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Robust free cash
- •Moderate returns
MarineMax combines strong liquidity and free cash flow with moderate profitability and manageable leverage, but carries premium valuation, large intangibles and material operating expenses that could constrain upside. #high-valuation
Price Behavior
Key Price Behavior Insights:
- •Rapid decline
- •Below SMA
- •Tight support
MMSI is in a short-term downtrend—down ~18.9% in the last month and trading ~9% below its last-month 21-day SMA, sitting on support near $66.71 with resistance at $73–$82.
Sharp ~18.9% drop from $82.21 to $66.71 over the last month indicating accelerated selling pressure
Sentiment & News
Key News Insights:
- •Strong cardiovascular demand
- •New endoscopy product
- •Downgrades & selling
Merit Medical beat Q4 estimates on strong cardiovascular demand and margins and launched a TTS esophageal stent, but investor downgrades, institutional selling and macro/OEM risks pushed the stock to a 52‑week low.
Operational momentum and product expansion support medium‑term growth, but near‑term share performance is likely constrained by analyst downgrades and macro/industry headwinds
Similar Companies in Healthcare
Other companies in the same sector with AI ratings